Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update
| Autor: | Jorrit De Waele, An Wouters, Evelien Smits, Filip Lardon, Yannick Verhoeven, Peter van Dam, Delphine Quatannens, Xuan Bich Trinh |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology cervical cancer medicine.medical_treatment Programmed Cell Death 1 Receptor Uterine Cervical Neoplasms Pembrolizumab Disease Review lcsh:Chemistry 0302 clinical medicine PD-1 Neoplasm Metastasis Immune Checkpoint Inhibitors lcsh:QH301-705.5 Spectroscopy Cervical cancer biology clinical trial General Medicine Neoplasm Proteins Computer Science Applications metastatic Chemistry 030220 oncology & carcinogenesis Biomarker (medicine) biomarker Female pembrolizumab immunotherapy Signal Transduction PD-L1 medicine.medical_specialty Antibodies Monoclonal Humanized Catalysis Inorganic Chemistry 03 medical and health sciences recurrent Internal medicine medicine Humans Physical and Theoretical Chemistry Molecular Biology Biology business.industry Organic Chemistry Cancer Immunotherapy medicine.disease Clinical trial 030104 developmental biology lcsh:Biology (General) lcsh:QD1-999 biology.protein Neoplasm Recurrence Local business |
| Zdroj: | International Journal of Molecular Sciences International journal of molecular sciences International Journal of Molecular Sciences, Vol 22, Iss 1807, p 1807 (2021) |
| ISSN: | 1422-0067 |
| Popis: | Even though cervical cancer is partly preventable, it still poses a great public health problem throughout the world. Current therapies have vastly improved the clinical outcomes of cervical cancer patients, but progress in new systemic treatment modalities has been slow in the last years. Especially for patients with advanced disease this is discouraging, as their prognosis remains very poor. The pathogen-induced nature, the considerable mutational load, the involvement of genes regulating the immune response, and the high grade of immune infiltration, suggest that immunotherapy might be a promising strategy to treat cervical cancer. In this literature review, we focus on the use of PD-1 blocking therapy in cervical cancer, pembrolizumab in particular, as it is the only approved immunotherapy for this disease. We discuss why it has great clinical potential, how it opens doors for personalized treatment in cervical cancer, and which trials are aiming to expand its clinical use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|